A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis.
Ten patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) were treated in an uncontrolled preliminary trial by oral administration of viable Lactobacillus casei strain Shirota (LcS) containing fermented milk. HTLV-1 provirus load, motor function, neurological findings, and immunological parameters were evaluated after 4 weeks. Although LcS did not change the frequencies or absolute numbers of all the examined cell surface phenotypes of peripheral blood mononuclear cells, NK cell activity was significantly increased after 4 weeks of oral administration of LcS preparation. Improvements in spasticity (modified Ashworth Scale scores) and urinary symptoms were also seen after LcS treatment. No adverse effect was observed in all the 10 patients throughout the study period. Our results indicated that LcS may be a safe and beneficial agent for the treatment of HAM/TSP; therefore randomized controlled studies are warranted.
Matsuzaki
Toshio
T
Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8520, Japan.
Saito
Mineki
M
Usuku
Koichiro
K
Nose
Hirohisa
H
Izumo
Shuji
S
Arimura
Kimiyoshi
K
Osame
Mitsuhiro
M
D000328:Adult; D000818:Animals; D015480:Deltaretrovirus Antibodies / Q000032:analysis; D004185:Disability Evaluation; D005260:Female; D005285:Fermentation; D005434:Flow Cytometry; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D007780:Lacticaseibacillus casei; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D008875:Middle Aged; D008892:Milk / Q000382:microbiology; D009128:Muscle Spasticity / Q000209:etiology / Q000503:physiopathology; D015493:Paraparesis, Tropical Spastic / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D010641:Phenotype; D019936:Probiotics / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D014555:Urination Disorders / Q000209:etiology / Q000503:physiopathology; D019562:Viral Load
D015480:Deltaretrovirus Antibodies